Quench Bio Springs From Atlas With $50M for a New Take on Inflammation
Summary
Quench Bio aims to develop drugs that stop the uncontrolled forms of programmed cell death, potentially halting inflammatory disease. Quench’s research focuses on gasdermin, a family of proteins that scientists have found plays a role in multiple signaling pathways that lead to inflammatory cell death. By blocking gasdermin d, a small molecule Quench drug could potentially stop the formation of the pores that leak a cell’s contents, the creation of which sets that cell on course for a violent death. Truex says the research that led to the formation of Quench stems from the Max Planck Society, where scientists were looking for drugs to block the NETosis inflammatory cell death pathway. Truex says that Quench has identified more than 25 autoinflammatory and autoimmune diseases associated with inflammatory cell death, including rheumatoid arthritis, lupus, multiple sclerosis, and nonalcoholic steatohepatitis.
Classifications
AskAI Classifications
LabelsLinked Companies
